Company: ZLAB
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001628280-25-008409
Chunk: 257

Company: Zai Lab Ltd
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 257
---
Year Ended December 31,Notes202420232022RevenuesProduct revenue, net10397,614 266,719 212,672 Collaboration revenue1,374 — 2,368 Total revenues398,988 266,719 215,040 ExpensesCost of product revenue(147,118)(95,816)(74,018)Cost of collaboration revenue(742)— — Research and development(234,504)(265,868)(286,408)Selling, general and administrative(298,741)(281,608)(258,971)Gain on sale of intellectual property— 10,000 — Loss from operations(282,117)(366,573)(404,357)Interest income37,105 39,797 14,582 Interest expenses(2,254)— — Foreign currency losses(15,137)(14,850)(56,403)Other income, net175,300 7,006 3,113 Loss before income tax and share of loss from equity method investment(257,103)(334,620)(443,065)Income tax expense11— — — Share of loss from equity method investment— — (221)Net loss(257,103)(334,620)(443,286)Loss per share — basic and diluted14(0.26)(0.35)(0.46)Weighted-average shares used in calculating net loss per ordinary share — basic and diluted989,477,730 966,394,130 958,067,140 

The accompanying notes are an integral part of these consolidated financial statements.

F-6

Zai Lab Limited 

Consolidated Statements of Comprehensive Loss 

(in thousands of $) 

Year Ended December 31,202420232022Net loss(257,103)(334,620)(443,286)Other comprehensive income, net of tax of nil:Foreign currency translation adjustments12,889 11,941 49,330 Comprehensive loss(244,214)(322,679)(393,956)

The accompanying notes are an integral part of these consolidated financial statements.

F-7

Zai Lab Limited 

Consolidated Statements of Shareholders’ Equity 

(in thousands of $, except for number of shares)

Ordinary sharesAdditionalpaidin capitalAccumulateddeficit Accumulatedothercomprehensiveincome (loss) Treasury Stock Number ofSharesAmountNumber ofShares Amount Total Balance at January 1,